Solid Biosciences to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's President and CEO, Bo Combo, along with Chief Medical Officer Gabriel Brooks, M.D., will deliver a presentation on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).

The presentation will be accessible via live webcast on the company's website's Investors section under Events, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.

News Market Reaction – SLDB

-4.50%

1 alert

-4.50% News Effect

On the day this news was published, SLDB declined 4.50%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When is Solid Biosciences (SLDB) presenting at the Jefferies London Healthcare Conference 2024?

Solid Biosciences will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).

How can investors watch Solid Biosciences' (SLDB) Jefferies Conference presentation?

Investors can watch the presentation via live webcast on the Events page of the Investors section of the Solid Biosciences website, with a replay available for 30 days afterward.

Who will represent Solid Biosciences (SLDB) at the 2024 Jefferies London Healthcare Conference?

Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will represent Solid Biosciences at the conference.

How can institutional investors meet with Solid Biosciences (SLDB) management at the Jefferies Conference?

Institutional investors interested in meeting with management can arrange meetings through their Jefferies representatives.